American Diabetes Association.Diabetes 1996: vital statistics. Alexandria. Va: American Diabetes Association. 1996.
2.
Campbell RKCampbell LK, White JRInsulin lispro: its role in the treatment of diabetes mellitus. Ann Phamiacother1996:30: 1263-71.
3.
White JRCampbell RKHirsch I.Insulin anatogues. New agents for improving glycemic control. Postgrad Med1997;101:58-70.
4.
Holleman F.Hoekstra JBInsulin lispro. N Engl J Med1997;337:176-83.
5.
Jehle PAFussgaenger RDKunze U.Dolderer M.Warchol W.Koop I.The human insulin analog insulin lispro improves insulin binding on circulating monocytes of intensively treated insulin-dependent diabetes mellitus patients . J Clin Endocrinol Metab1996;81:2319-27.
6.
Zinman B.Tildesley H., Chiasson JL, Tsui E., Strack T.Insulin lispro in CSII: results of a double-blind crossover study . Diabetes1997;46: 440-43.
7.
Torlone E., Fanclli C., Ramhotti AM, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia1994:37:713-20.
8.
Bohannon Njv.Benefits of lispro insulin. Control of postprandial glucose levels is within reach. Postgrad Med1997;1101:73-80.
9.
The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993;329(14): 977-86.
10.
Reichard P.Berglund B., Britz A., Cars I.Nilsson BYRusenqvist U.Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intem Med1991 : 230:101-8.
11.
Marcus AOFernandez MPInsulin pump therapy. Acceptable alternative to injection therapy . Postgrad Med1996:99:125-43.
12.
Unger JR, Fredrickson LPA primer on intensive diabetes management and insutin pump therapy . Primary Care Rep1997;3:9-18.
13.
American Diabetes Association.Standards of medical care for patients with diabetes mellitus. Diabetes Care1995;18:8-15.
14.
Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes1997;46: 265-70.
15.
Kotsanos JG , Vignati L., Huster W., et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care1997 ;20:948-58.
16.
Eheling P.Lalli C., Jansson P-A.Bolli GB, Smith U.Koivisto VAStrategies toward improved control during insulin lispro therapy in IDDM. Diabetes Care1997;20:1287-89.